Skip to main content

Table 1 QLQ-CIPN20, PRO-CTCAE™, and TNSc© Sample statistics at each study visit

From: Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors

Measure Mean (SD) Median (range) Proportion at floor (%) Proportion at ceiling (%)
PRO-CTCAE numbness and tingling severity     
T1 (n = 140) 0.79 (0.78) 1 (0–3) 57 (40.7%) 0
T2 (n = 137) 0.91 (0.84) 1 (0–3) 50 (36.5%) 0
T3 (n = 138) 1.08 (0.88) 1 (0–4) 40 (29%) 1 (0.07%)
T4 (n = 123) 1.03 (0.83) 1 (0–3) 35 (28.5%) 0
PRO-CTCAE numbness and tingling interference     
T1 (n = 139) 0.25 (0.54) 0 (0–2) 111 (79.9%) 0
T2 (n = 140) 0.49 (0.79) 0 (0–3) 93 (66.4%) 0
T3 (n = 138) 0.55 (0.76) 0 (0–3) 83 (60.1%) 0
T4 (n = 126) 0.52 (0.72) 0 (0–3) 76 (60.3%) 0
QLQ-CIPN20 sensory     
T1 (n = 140) 7.84 (10.51) 3.70 (0–55.56 56 (40%) 0
T2 (n = 140) 11.02 (11.02) 7.41 (0–55.56) 33 (23.6%) 0
T3 (n = 138) 11.92 (11.88) 7.41 (0–55.56) 33 (23.9%) 0
QLQ-CIPN20 motor     
T1 (n = 140) 5.15 (7.60) 0 (0–37.5) 75 (53.6%) 0
T2 (n = 139) 7.61 (9.74) 4.17 (0–50) 58 (41.7%) 0
T3 (n = 138) 8.49 (10.57) 4.17 (0–54.17) 54 (39.1%) 0
010 NRS of worst CIPN pain Intensity     
T1 (n = 138) 1.41 (1.98) 0 (0–9) 71 (51.4%) 0
T2 (n = 139) 1.99 (2.41) 1 (0–10) 61 (43.9%) 0
T3 (n = 138) 1.97 (2.16) 1 (0–9) 58 (42%) 0
TNSc©     
T3 (n = 118) 6.75 (2.9) 7 (1–13) 0 0
  1. Table describes sample statistics for PRO-CTCAE item (Range = 0–4) QLQ-CIPN20 sensory and motor subscale (Range = 0–100), 0–10 NRS of worst CIPN pain intensity (Range = 0–10) and TNSc© (Range = 0–20) scores at each study time point (T1–T4). Higher scores on all measures represent worse CIPN severity
  2. CIPN-Chemotherapy-Induced Peripheral Neuropathy, PRO-CTCAE™—Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events, QLQ-CIPN20-Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Scale, TNSc©—Total Neuropathy Score-Clinical Version